Is Therapeutic Use of Psychedelic Medication Influenced by Bias?

Abstract

Get full access to this article

View all access options for this article.

References

Barnett

B. S.

Parker

S. E.

Weleff

(2022). United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020. International Journal of Drug Policy, 99, Article 103473. https://doi.org/10.1016/j.drugpo.2021.103473

Begola

J. J.

Schillerstrom

J. E.

(2019). Halluciogens and their therapeutic use: A literature review. Journal of Psychiatric Practice, 25, 334–346. https://doi.org/10.1097.PRA.0000000000000409

Begola

M. J.

Dowben

J. S.

(2018). The re-emergence of hallucinogenic research. Perspectives in Psychiatric Care, 54, 523–526. https://doi.org/10.1111/ppc.12263

Davis

A. K.

Barrett

F. S.

May

D. G.

Cosimano

M. P.

Sepeda

N. D.

Johnson

M. W.

Finan

P. H.

Griffiths

R. R.

(2021). Effects of Psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry, 78, 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285

Fradkin

(2021). Psilocybin: A brief overview for psychiatric mental health nurse practitioners. Perspectives in Psychiatric Care, 58, 1200–1203. https://doi.org/10.111/ppc12888

Garcia-Romeu

Richards

W. A.

(2018). Current perspectives on psychedelic therapy: Use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry, 30, 291–316. https://doi.org/10.1080/09540261.2018.1486289

Grieco

S. F.

Castren

Knudsen

G. M.

Kwan

A. C.

Olson

D. E.

Zuo

Holmes

T. C.

(2022). Psychedelics and neural plasticity: Therapeutic implications. Journal of Neuroscience, 42, 8439–8449. https://doi.org/10.1523/JNEUROSCI.1121-22.2022

Heal

D. J.

Smith

S. L.

Belouin

S. J.

Henningfield

J. E.

(2023). Psychedelics: Threshold of a therapeutic revolution. Neuropharmacology, 236, Article 109610. https://doi.org/10.1016/j.neuropharm.2023.109610

Mocanu

Mackay

Christie

Argento

(2022). Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy. Substance Abuse Treatment, Prevention, and Policy, 17, Article 37. https://doi.org/10.1186/s13011-022-00468-0

10.

The National Library of Medicine National Center for Biotechnology Information website. (n.d.). https://clinicaltrials.gov/

11.

Nichols

D. E.

(2016). Psychedelics. Pharmacology Review, 68, 264–355. https://doi.org/10.1124/pr.115.011478

12.

Nichols

D. E.

Walter

(2021). The history of psychedelics in psychiatry. Psychopharmacology, 54, 151–166. https://doi.org/10.1055/a-1310-3990

13.

Penn

Dorsen

C. G.

Hope

Rosa

W. E.

(2021). Psychedelic-assisted therapy: Emerging treatments in mental health disorders. American Journal of Nursing, 121, 34–40. https://doi.org/10.1097/01.NAJ.0000753464.35523.29

14.

Preuss

C. V.

Kalava

King

K. C.

(2023). Prescription of controlled substances: Benefits and risks. StatPearls Publishing.

15.

Siegel

A. N.

Meshkat

Benitah

Lipsitz

Hartej

Lui

L. M. W.

Teopiz

K. M.

McIntyre

R. S.

Rosenblat

J. D.

(2021). Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Journal of Psychiatric Research, 139, 71–81. https://doi.org/10.1016/j.psychires.2021.05.019

16.

Smith

W. R.

Appelbaum

P. S.

(2021). Two models of legalization of psychedelic substances: Reasons for concern. Journal of the American Medical Association, 326, 697–698. https://doi.org/10.1001/jama.2021.12481